Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Kendle, Invida and Global Research Services (GRS).
Respiratory formulations specialist Vectura has licensed two dry-formulation technologies to GSK, further strengthening its position in the $25bn (€19bn) asthma and COPD market.
Quintiles says it is confident that all proper procedures were followed during a 2006 study of Theravance’s antibiotic telvancin being audited by Indian drug regulators.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Watson Pharmaceuticals, Shire, Lupin and AmerisourceBergen.
Cel-Sci’s recently opened “Cold fill” facility has passed its first manufacturing test by completing filling of a batch of the candidate head and neck cancer drug Multikine for a late-stage trial.
Penwest Pharmaceuticals raises guidance citing Opana ER royalties, deals and patent settlements as Q2 highlights; but warns that job cuts likely under cost cutting plan.
Ampac Fine Chemicals posted a 28 per cent jump in revenues in the third quarter but this was offset by manufacturing inefficiencies and validation costs.
World Courier is continuing its period of rapid expansion by breaking ground on a 135,000 sq ft clinical trial storage and distribution centre in Singapore.
AMRI recorded a $6.0m (€4.6m) operating loss in the second quarter as restructuring charges and the lack of milestone payments offset contract service gains.
Ockham looks east for patient recruitment, setting up partnership with Russlan Clinical Research (RCR) to increase access to in-demand clinical trial destination.
High tech packaging sales and revenue from acquired delivery businesses drive West Pharmaceutical Services growth in second quarter, but US firm cuts guidance.
In the first of a series of special in-pharmatechnologist podcasts Kate Wilber, Image Solutions’ (ISI) director of regulatory Services, Europe discusses the emerging trends in BPO and talks about how it can benefit drugmakers.
Greater recognition of toxicity risks of HPAPIs and continued growth of oncology sector are driving drug industry demand for safe manufacturing capacity says US fine molecules firm SAFC Pharma.
Recently-acquired Italian R&D facility helps Aptuit win new contract after local neuroscience-focused developer Siena Biotech names the CMO as “supplier of choice.”
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Roche, Caraco, CMP Therapeutics and Unilife.
Charles River Laboratories (CRL) has abandoned plans to buy Wuxi Pharmatech after the $1.6bn (€1.2bn) takeover failed to gain sufficient shareholder support.
Demand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.
Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).
Icon reported a dip in operating income in the second quarter but an upturn in new business, and the cash to pursue M&A, make it reasonably positive about the future.
Japanese researchers look set to have another option for biomarker analysis, after Thermo Fisher Scientific unveils plans for Tokyo research laboratory unit.
Research into the use of quadrupole resonance spectroscopy (QR) for non-invasive, non-destructive detection of counterfeits has been boosted by a grant.
CRO Quintiles says biomarkers give insight into cancer drug candidates’ efficacy earlier in the development process, reducing trial costs and duration.
Colorcon will buy Indian group Pharmaceuitcal Coatings to expand both its tablet film coating business and presence in “rapidly growing” pharmaceutical market.